GlassScriptPhysician profile
Theodore J Williams
NPI 1114914546
$3,912.25
in general payments reported to CMS, 2019-2025
40 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $813 · 2020: $947 · 2021: $1,067 · 2022: $24.48 · 2023: $163 · 2024: $401 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,060.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $509.62 | 2019-2025 | |
| Amarin Pharma, INC. | $465.47 | 2019-2021 | |
| Amgen INC. | $330.35 | 2019-2021 | |
| Forte Bio-Pharma LLC | $260.91 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Novo Nordisk INC | $233.17 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.66 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $207.08 | 2019-2021 | |
| Protega Pharmaceutials INC | $187.22 | 2025 | Roxybond |
| Lilly USA, LLC | $186.60 | 2019-2024 | Emgality, Reyvow |
| Pfizer INC. | $154.51 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $132.19 | 2023-2025 | Belbuca, Xtampza |
| Antares Pharma, INC. | $97.27 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $94.03 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $77.56 | 2021 | |
| Braeburn INC. | $77.10 | 2024 | Brixadi |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.